2008-12-03 10:58:13 -

Inquiries:
Roger Boutin
Director of Marketing
PRA International, Inc.
Ph: 1+434-951-3924

Tim Grace
Financial Relations Board
Ph: 1+312-640-6667

FOR IMMEDIATE RELEASE:

PRA INTERNATIONAL ANNOUNCES COLLABORATION WITH FRONTAGE LABORATORIES INC.
Partnership extends PRA bioanalytical services in North America

2 December 2008, Raleigh, N.C. - PRA International, a leading Clinical
Research Organization (CRO), announced today a collaborative agreement with
Frontage Laboratories Inc. This partnership enables PRA Early Development
Services' US Clinical Pharmacology Center (PRA EDS US

CPC) to now offer a
full complement of analytical lab testing services to its existing Phase I -
IV clinical trial services in North America.

PRA's state-of-the-art, 80-bed Lenexa clinical facility near Kansas City,
Missouri, runs a multitude of Phase I and Phase IIa studies each year, with
a particular focus on first in human studies and other complex PK studies.
By meaningfully broadening its bioanalytical service portfolio, PRA now
offers Pharma and Biotech sponsors and other CROs the ability to align the
clinical and laboratory processes, thus saving time by avoiding unnecessary
clinical trial delays. It already operates a comparable full-service
offering in Europe.

Although PRA conducts clinical trials across a broad spectrum of therapeutic
areas, it has a special emphasis in the areas of oncology, central nervous
system, allergy/respiratory, cardiovascular disorders and infectious
diseases. Frontage Laboratories Inc. is fully compliant with cGMP/GLP
regulations and under this new collaboration will offer specialized
bioanalytical services via PRA. The new collaboration also offers
pharmacokinetic & biostatistical consultancy and data support (including
data management, biostatistical and PK/PD analysis and ICH-compliant report
writing). Frontage operates a bioanalytical and biomarker research center of
excellence in Malvern, PA (near Philadelphia), that houses 17 mass
spectrometers and other state-of-the-art instrumentation. Frontage
Laboratories' client focus and project management efforts align well with
PRA's strategic initiatives.

Dr Wim Tamminga, Senior Director, PRA EDS US CPC commented, "We selected
Frontage Laboratories as part of our strategy to offer clients a seamless
package consisting of clinical and laboratory services,. This service
allows us to accelerate Phase I studies and to give sponsors the ability to
make better decisions earlier in the drug development process. Frontage is
the right partner for this collaboration because they are already a
well-established provider of cGMP/GLP compliant testing services. Quality
of service, location, and scientific knowledge are what make Frontage
Laboratories the best collaborative partner for our bioanalytical services."

Song Li, CEO, Frontage Laboratories, Inc. also noted, "We are delighted that
PRA chose Frontage Laboratories to assist in delivering service excellence
to all clients and customers across the United States. Our scientific team
is recognized industry wide for their expertise in solving complex
bioanalytical method development issues quickly and cost effectively,
allowing our clients to advance to Phase I studies faster. We look forward
to building a collaborative relationship with PRA that not only streamlines
project execution but also places a strong emphasis on project management."

With more than 3,300 employees on six continents, PRA delivers reliable
service, program-level therapeutic expertise and easy global access to
knowledge. PRA offers a broad array of services that encompass the entire
spectrum of clinical development, from filing of Investigational New Drug
(IND) and similar regulatory applications to product registration and
post-marketing studies on a global basis.

About PRA International
PRA International is a global Clinical Research Organization providing
services through all phases of clinical development. Although we specialize
in Oncology, CNS, respiratory/allergy diseases, cardiovascular and
infectious diseases, we perform studies in all therapeutic areas. PRA has
supported over 2,100 clinical trials through its 30 global offices. PRA's
therapeutic expertise, global reach and project experience, combined with
local knowledge, enable our project teams to deliver consistent and on time
performance for our clients. PRA's Early Development Services (EDS) group
provides comprehensive services for Phase I and Phase IIa studies,
including: Phase I and IIa clinical research, bioanalytical research and
data support.

To learn more about PRA International, please visit
www.prainternational.com, email endpoints@praintl.com or call our
Global Headquarters at +1 (919) 7868200.

For more information on PRA bioanalytical services, please contact Peter
Ketelaar, Vice President Bioanalytical Laboratory at
KetelaarPeter@PRAIntl.com or phone: +31-653-335-810

About Frontage Laboratories Inc.
Based in Malvern, PA, Frontage Laboratories, Inc. is a full service,
collaborative research and development company that provides bioanalytical
and biomarker services, pharmaceutical analysis, formulation development,
GMP clinical trial materials (CTM) manufacturing and preclinical study
services. Frontage is facilitating the rapid development of NCE's and
generic products through its operations in the US and China. Frontage
assists its clients with resolving complex product development issues and
advancing drug candidates through preclinical and clinical development
stages to commercialization.

For more information about Frontage and its services, please contact Ron
Connolly, Sr. Vice President Operations at rconnolly@frontagelab.com, visit
the website www.frontagelab.com, or phone +01-610-232-0100

- ENDS -

For further press information please contact Fiona Robinson, The Scott
Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA,
United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email:
fer@scottpr.com